The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Phase II results of rituximab and epcoritamab as 1L therapy for patients with high-tumor-burden FL
Reid Merryman, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the results of a Phase II study (NCT05783609) evaluating rituximab pretreatment followed by epcoritamab in newly diagnosed, high-tumor-burden follicular lymphoma (FL). The time-limited regimen demonstrated promising results, with high response rates and a tolerable safety profile, supporting a potential chemotherapy-free first-line (1L) approach for selected patients. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
